chirurgisch gerelateerd spierverlies Surgical Related Muscle Loss (SRML)
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Female or male aged at least 18 years; * The patient must speak the Dutch language; * The patient understands the purpose of the study and has given written informed consent to participate in the study; * Diagnosed or the suspicion of a liver tumour (primary cancer or colorectal liver metastases), pancreatic malignancy, bile duct malignancy, colon tumour, rectum tumour, or pseudomyxoma peritonei; * Scheduled for open major abdominal surgery consisting of the following surgical procedures: o Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy) (CRS with HIPEC) o (Sub)total pelvic exenteration o Pylorus preserving pancreaticoduodenectomy (PPPD) o Whipple procedure (classic pancreaticoduodenectomy) o Subtotal pancreatectomy o Total pancreatectomy o Major liver resection, defined as *3 liver segments * The patient will be operated at the UMCG; * Presence of a preoperative CT-scan of the abdomen.
Exclusion criteria
Exclusion criteria: * Scheduled for laparoscopic surgery; * Minor liver resections, defined as
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Our main objective is to measure the amount of clinically relevant SRML (defined as *5% muscle loss within one week measured by the CSA of the different muscles) in cancer patients after major abdominal surgery for pseudomyxoma peritonei, pancreatic, liver and colorectal cancer by using bedside ultrasound and squeeze and force measurements of arms and legs. | — |
Secondary
| Measure | Time frame |
|---|---|
| For the different secondary endpoints the included group of patients will be divided in two subgroups: * Clinically relevant SRML (*5% muscle loss within seven days) and * Clinically not relevant SRML ( | — |
Countries
Netherlands
Outcome results
None listed